- Company
- Bayer to withdraw Levitra from Korean market
- by Kim, Jin-Gu Feb 4, 2020 06:31am
- Bayer Korea has decided to withdraw Levitra (vardenafil) from Korean market and leave Chong Kun Dang Pharmaceutical’s Yaila as the only erectile dysfunction treatment in Korea with vardenafil. Bayer Korea has notified respective drug distributing vendors that the supply of Levitra would be suspended from coming April. Superficially,
- Company
- Talks resume on listing SGLT2 inhibitor combination therapy
- by Eo, Yun-Ho Jan 31, 2020 06:36am
- “Until the spring seminar, the association will have an official statement and deliver it to the government.” The Korean Diabetes Association (KDA) started fine tuning their opinions about expanding reimbursement on combination therapy consisting of sodium-glucose transport protein 2 (SGLT2) inhibitor. On Jan. 30, KDA convened a pre
- Company
- Tae-han Kim, CEO of BioLogics will be reappointed
- by Lee, Seok-Jun Jan 31, 2020 06:36am
- Samsungbioepis will operate the system of two vice presidents, and Tae-han Kim, CEO of SamsungbioLogics has confirmed that it is four consecutive years. The two companies made such key positions on January 30. The figures reflect results from last year's performance. Seven people were promoted. Another vice president was appointed.
- Company
- Resumed supply of Terramycin delayed from Feb to July
- by Jung, Hye-Jin Jan 31, 2020 06:35am
- The supply resumption date of Pfizer Korea’s Terramycin ophthalmic ointment has been pushed back. On Jan. 28, Pfizer Korea notified distributors, pharmacies and hospitals that Terramycin supply would resume around July. Apparently, the delayed production schedule is pushing down the resumption date. In last November, the company has
- Company
- Keytruda awaits Cancer Committee’s nod in February
- by Eo, Yun-Ho Jan 30, 2020 06:34am
- The pharmaceutical industry is keeping their eyes close to the Korean government and MSD’s tug-of-war over expanding reimbursement on immunotherapy Keytruda. The industry reported on Jan. 30, the Cancer Disease Deliberation Committee is scheduled to deliberate reimbursement on Keytruda’s five indications including first-line treatment
- Company
- ‘No Japan’ no effect on drug trade with Japan last year
- by Kim, Jin-Gu Jan 30, 2020 06:33am
- Apparently, imported drug volume from Japan has gone up in last year by 8.3 percent. Experts analyze Koreans boycotting Japanese products took off from the latter half of last year had not affected the pharmaceutical industry. According to import and export statistics disclosed by Korea Customs Service on Jan. 28, Korean drug export volume t
- Company
- A Employee, ahead of retirement at Merck, took his own life
- by Eo, Yun-Ho Jan 29, 2020 10:55am
- There was a pity that a salesperson at Merck Bio Pharma, who was about to leave, took his own life. According to the industry, Mr. A, a sales representative from Daejeon Branch of Merck, was found dead. Mr. A was included in the Early Retirement Program (ERP) during the sale of Merck's General Medicine primary care (GM) division, and re
- Company
- Breakthrough anticancer Tagrisso makes KRW 29 billion
- by An, Kyung-Jin Jan 29, 2020 06:26am
- AstraZeneca’s new lung cancer treatment Tagrisso has continued to top the prescription drug market. After two years of reimbursement listing, the new drug has generated almost 30 billion won and expanded the overall epidermal growth factor (EGFR) targeted therapy prescription volume. According to pharmaceutical product research firm UBI
- Company
- Eylea biosimilar by SCD applies for Phase 3 global IND
- by Lee, Seok-Jun Jan 29, 2020 06:25am
- Samchundang Pharm (SCD) plans to have Phase 3 global clinical trial protocol approved for Eylea’s biosimilar ‘SCD411’ within the first quarter of the year. The protocol approval would be reviewed for 90 days at longest, and green light the company to start the Phase 3 trial by the coming second quarter. The multiregional study is planned
- Company
- General hospitals clear Norvasc for pediatric use
- by Eo, Yun-Ho Jan 28, 2020 11:18am
- More general hospitals are reportedly listing Norvasc on their drug codes for pediatric treatment. Pharmaceutical industry on Jan. 28 said respective Drug Committees in Seoul National University Hospital, Severance Hospital and Korea University Guro Hospital cleared Norvasc (Amlodipine) 2.5 mg for prescription from the release in last ye
